LISINOPRIL TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

LISINOPRIL

Disponible depuis:

SORRES PHARMA INC

Code ATC:

C09AA03

DCI (Dénomination commune internationale):

LISINOPRIL

Dosage:

5MG

forme pharmaceutique:

TABLET

Composition:

LISINOPRIL 5MG

Mode d'administration:

ORAL

Unités en paquet:

100/500

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Descriptif du produit:

Active ingredient group (AIG) number: 0121550003; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2014-06-20

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
PR
LISINOPRIL
(lisinopril tablets, USP)
Tablets 5, 10 and 20 mg
Angiotensin Converting Enzyme Inhibitor
SORRES PHARMA INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of Revision:
April 19, 2011
Submission Control No: 145664
2
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
LISINOPRIL
(lisinopril tablets, USP)
Tablets 5, 10 and 20 mg
THERAPEUTIC CLASSIFICATION
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an ACE inhibitor which is used in the treatment of
hypertension, congestive heart
failure and following myocardial infarction in hemodynamically stable
patients.
Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum K
+
. In patients treated with lisinopril
and a thiazide
diuretic there was essentially no change in serum potassium (see
PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of lisinopril has not
been associated with a rapid
increase in blood pressure. In most patients studied, after oral
administration of an individual
dose of lisinopril, the onset of antihypertensive activity is seen at
one hour with peak reduction
of blo